Thrombosis and hormone replacement therapy in the menopausal
Hormonal replacement therapy (HRT) for treatment of menopausal and climacterically complaints is associated with a three- to four -fold increase in the risk of thrombosis. The actual risk of thrombosis depends on the type and the hormone content of the preparation in use but also on the individual risk factors of the patient.
This means that prior to the commencement of HRT a careful evaluation of the individual’s thrombotic risk should be performed in every woman in order to choose the most effective, thrombosis risk adapted hormone combination and method of application accordingly. On the other hand, a history of thrombosis does not necessarily contraindicate the use of hormonal replacement therapy.